User login
Key clinical point: Statin use is associated with a lower risk for hepatocellular carcinoma (HCC) incidence in dialysis patients with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection.
Major finding: Statin users vs nonusers had a 41% reduced risk for HCC (subdistribution hazard ratio 0.59; P = .001) and a lower weighted HCC incidence rate (incidence rate difference −3.7; P < .001), with the incidence rate ratio being 0.56 (P < .001).
Study details: This retrospective observational study included 6165 patients aged ≥ 19 and < 85 years with HBV or HCV infection who were on maintenance dialysis and received ≥28 cumulative defined daily doses of statins (users; n = 2655) or did not receive statins (nonusers; n = 3510) in the first 3 months after dialysis commencement.
Disclosures: No financial support was reported. The authors declared no conflicts of interest.
Source: Kim HW et al. Association of statin treatment with hepatocellular carcinoma risk in end-stage kidney disease patients with chronic viral hepatitis. Sci Rep. 2022;12:10807 (Jun 25. Doi: 10.1038/s41598-022-14713-w
Key clinical point: Statin use is associated with a lower risk for hepatocellular carcinoma (HCC) incidence in dialysis patients with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection.
Major finding: Statin users vs nonusers had a 41% reduced risk for HCC (subdistribution hazard ratio 0.59; P = .001) and a lower weighted HCC incidence rate (incidence rate difference −3.7; P < .001), with the incidence rate ratio being 0.56 (P < .001).
Study details: This retrospective observational study included 6165 patients aged ≥ 19 and < 85 years with HBV or HCV infection who were on maintenance dialysis and received ≥28 cumulative defined daily doses of statins (users; n = 2655) or did not receive statins (nonusers; n = 3510) in the first 3 months after dialysis commencement.
Disclosures: No financial support was reported. The authors declared no conflicts of interest.
Source: Kim HW et al. Association of statin treatment with hepatocellular carcinoma risk in end-stage kidney disease patients with chronic viral hepatitis. Sci Rep. 2022;12:10807 (Jun 25. Doi: 10.1038/s41598-022-14713-w
Key clinical point: Statin use is associated with a lower risk for hepatocellular carcinoma (HCC) incidence in dialysis patients with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection.
Major finding: Statin users vs nonusers had a 41% reduced risk for HCC (subdistribution hazard ratio 0.59; P = .001) and a lower weighted HCC incidence rate (incidence rate difference −3.7; P < .001), with the incidence rate ratio being 0.56 (P < .001).
Study details: This retrospective observational study included 6165 patients aged ≥ 19 and < 85 years with HBV or HCV infection who were on maintenance dialysis and received ≥28 cumulative defined daily doses of statins (users; n = 2655) or did not receive statins (nonusers; n = 3510) in the first 3 months after dialysis commencement.
Disclosures: No financial support was reported. The authors declared no conflicts of interest.
Source: Kim HW et al. Association of statin treatment with hepatocellular carcinoma risk in end-stage kidney disease patients with chronic viral hepatitis. Sci Rep. 2022;12:10807 (Jun 25. Doi: 10.1038/s41598-022-14713-w